Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 16 of 38, showing 5 Applications out of 189 total, starting on record 76, ending on 80

# Protocol No Study Title Investigator(s) & Site(s)

76.

ECCT/24/06/05   SII-qHPV Vaccine Study
    A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years.   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
2. KEMRI - CCR Nairobi (Nairobi City county)
 
View

77.

ECCT/15/12/05   Post-discharge Malaria Chemoprevention(PMC) study
    Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial   
Principal Investigator(s)
1. Titus Kwambai
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Migori County Referral Hospital (Migori county)
4. Busia County Referral Hospital (Busia county)
 
View

78.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
View

79.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
View

80.

ECCT/21/02/01   PTSD 102 TONIX
    A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308).   
Principal Investigator(s)
1. Prof. Lukoye Atwoli
Site(s) in Kenya
1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county)
2. KEMRI Nairobi (Nairobi City county)
3. Aga Khan University Hospital (Nairobi City county)
 
View